Navigation Links
AutoImmune Inc. Reports 2009 Second Quarter Financial Results
Date:8/6/2009

PASADENA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2009, compared with a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2008. For the six months ended June 30, 2009, the net loss was $256,000, or $0.02 per share basic and diluted, compared with net loss of $193,000, or $0.01 per share basic and diluted for the same period in 2008. As of June 30, 2009, the Company reported $8.2 million in cash and marketable securities as compared to $8.5 million in cash and marketable securities as of December 31, 2008.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales in the first six months of 2009 at Colloral LLC, our joint venture with Deseret Laboratories, Inc., more than doubled from the same period in 2008. The response to marketing through our licensee, Bronson Laboratories, LLC remains encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights pertaining to an injectable therapy for the treatment of multiple sclerosis to BioMS. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of all products covered by the license agreement. BioMS Medical Corp. and Eli Lilly and Company recently reported that dirucotide, the lead drug covered by AutoImmune's license agreement with BioMS, did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there we
'/>"/>

SOURCE AutoImmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AutoImmune Inc. Reports 2009 First Quarter Financial Results
2. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
3. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
4. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
8. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
9. Synthetech Reports First Quarter Fiscal 2010 Results
10. GenVec Reports Second Quarter 2009 Financial Results
11. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 Research and ... "Global DNA Diagnostics Market (Product types, Application, ... Global Trends, Company Profiles, Demand, Insights, Analysis, Research, ... report to their offering. ... applications, techniques, end users and Geography) Global Size, ...
(Date:10/22/2014)... 22, 2014 Involution Studios , ... of a new infographic, Understanding Ebola . ... beautifully designed, easy to follow informative tool for anyone ... outbreak, symptoms and prevention. , "As the news has ... 2014 Ebola outbreak represents not only a healthcare crisis ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... 16 N-Viro International,Corp. (OTC Bulletin Board: NVIC) ("N-Viro") ... lawsuit in favor of N-Viro and certain past,and/or current ... 2006 by the former CEO, President and Chairman of ... granting the dismissal, the Honorable,James G. Carr, Chief Judge ...
... Answer Questions About Stockholder Meeting October 23, ... ISOT ) ("IsoTis"), an orthobiologics company, today announced ... held on,October 11, 2007 and adjourned to October ... approximately 2,555,000 shares, 36 percent,of the shares entitled ...
... Oct. 15 EpiCept Corporation,(Nasdaq and OMX Nordic ... Director of Lead Discovery, will be presenting at ... the Hotel Del Coronado in San Diego, CA,on ... advances into pre-clinical,testing of drug discovery efforts targeting ...
Cached Biology Technology:N-Viro International Corporation Announces Dismissal of Lawsuit Against It 2IsoTis Reports Interim Results of Vote for Integra Merger 2IsoTis Reports Interim Results of Vote for Integra Merger 3IsoTis Reports Interim Results of Vote for Integra Merger 4EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 2EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 3EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 4EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 5
(Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... of scientists at the CSIC has shown that temperature can ... team led by Josep Vilardell, ICREA scientist at the CSIC,s ... its effects on RNA structure, can control how the genetic ... published this week in Molecular Cell. Hiding ...
... MD The Federation of American Societies for Experimental ... client, the Histochemical Society (HCS). The executive leadership ... include general management support, membership marketing, recruitment, and retention, ... Executive Director of HCS, William Stahl, PhD commented, "HCS ...
... that mirrors both symptoms of the disease and the ... by University of Chicago researchers, according to a new ... neurotransmitter receptor in a specific brain region responsible for ... cause of the disorder. Further research with the model ...
Cached Biology News:Temperature controls the genetic message 2New model for treatment of obsessive-compulsive disorder created 2New model for treatment of obsessive-compulsive disorder created 3
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
...
...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Biology Products: